At the news
? BULLISHIMPACT 8/10 PRESS-RELEASE filed Apr 14, 2026 at 07:30 ET
Praxis Precision Medicines announced that the FDA has accepted its New Drug Application (NDA) for ulixacaltamide HCl to treat essential tremor, with a PDUFA target action date of January 29, 2027. The FDA does not plan to hold an advisory committee meeting, accelerating the review timeline.
- FDA accepted NDA for ulixacaltamide HCl for essential tremor with PDUFA date of January 29, 2027
- No advisory committee meeting planned, indicating streamlined review process
- NDA supported by positive Phase 3 Essential3 trial results showing statistically and clinically significant efficacy
- Ulixacaltamide received Breakthrough Therapy Designation in December 2025
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access